YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE.
 
                   ==ASTHMA AND BOWEL DISORDER==
 
1
AUTHOR                    Frost RE
AUTHOR                    Messiha FS
TITLE                     Clinical uses of lithium salts.
SOURCE                    Brain Res Bull; VOL 11, ISS 2, 1983, P219-31
                          (REF: 267)
ABSTRACT                  A comprehensive overview of the clinical
                          aspects of lithium therapy is presented.
                          Emphasis is placed on recent developments
                          regarding the clinical uses of Li2CO3 in
                          non-psychiatric conditions. The established
                          efficacy of the drug in the treatment and
                          prophylaxis of mania and bipolar affective
                          disorders is noted, and the evidence
                          supporting the use of lithium salts as a
                          prophylactic agent in unipolar depression,
                          aggressive behavior, schizophrenic disorders
                          and organic brain dysfunction is discussed.
                          The use of lithium carbonate in various
                          disorders of movement and in certain
                          extrapyramidal diseases is summarized, as are
                          the results of its trials in alcoholism and
                          drug abuse. In addition, uses of Li2CO3 in
                          asthma, thyroid diseases, granulocytopenia,
                          headache, bowel disease, anesthesiology,
                          cardiology, and sleep disorders are
                          summarized. The data suggests the potential
                          effectiveness of Li2CO3 in a variety of
                          clinical conditions other than those for
                          which it is classically indicated, provided
                          more detailed double-blind studies are
                          performed.
 
 
YOU ARE NOW CONNECTED TO THE MEDLINE (1994 - 97) FILE. 
 
1 
AUTHOR                    Collins SM 
TITLE                     Similarities and dissimilarities between 
                          asthma and inflammatory bowel diseases. 
SOURCE                    Aliment Pharmacol Ther 1996;10 Suppl 2:25-31 
ABSTRACT                  Because both asthma and inflammatory bowel 
                          disease are chronic relapsing inflammatory 
                          conditions, comparisons are inevitable. Both 
                          disorders reflect the convergence of 
                          environmental trigger factors in genetically 
                          predisposed individuals. The genetic 
                          preposition may be on a polygenic basis or on 
                          the basis of genetic heterogeneity. 
                          Environmental factors that may trigger the 
                          expression or relapse in asthma and 
                          inflammatory bowel disease include: cigarette 
                          smoking (in Crohn's but not in ulcerative 
                          colitis), the use of non-steroidal 
                          anti-inflammatory drugs in asthma and Crohn's 
                          disease), infection and possibly stress. TH 
                          lymphocytes are currently believed to be 
                          important in asthma and in Crohn's disease 
                          but not in ulcerative colitis. IgE-activated 
                          eosinophils and mast cells are central to the 
                          maintenance of asthma but do not play such a 
                          crucial role in inflammatory bowel disease. 
                          TH2 cytokines including IL-4 and IL-5 are 
                          believed to be important in the inflammatory 
                          response of asthma, and TH cytokines are 
                          believed to be in Crohn's disease but a TH1 
                          or TH2 subclassification is not currently 
                          evident. The hallmark of asthma is increased 
                          reactivity of the airways, in terms of 
                          bronchoconstriction. Altered physiology also 
                          accompanies inflammatory bowel disease but 
                          hyperactivity is not an invariable feature. 
                          Finally, it is becoming increasingly evident 
                          that neural influences modulate inflammatory 
                          processes and this is likely to be relevant 
                          to both asthma and inflammatory bowel 
                          disease.